Transrectal anterior zone sampling of the prostate may be a viable alternative to transperineal template biopsies in patients with negative previous biopsies and with rising PSA or persistently elevated PSA, researchers from the United Kingdom report.
African-American men eligible for active surveillance have a higher risk of advanced cancer on final surgical pathology compared to Caucasian men, suggesting the need for more stringent criteria for active surveillance for African-American men, according to a recently published study.
Researchers have shown, via a phase I trial, that the relationship between nerves and prostate cancer in perineural invasion is susceptible to therapeutic intervention with neurotoxic agents such as onabotulinumtoxinA (Botox).
EDAP TMS said the FDA has provided a positive filing review notification on the company’s pre-market approval application for its Ablatherm Integrated Imaging HIFU (high-intensity focused ultrasound) device for the treatment of low-risk, localized prostate cancer.
A single PSA test at 45 years of age may help predict long-term risk of developing aggressive prostate cancer, according to a recent study.
New evidence from the second-largest section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) suggests that prostate cancer screening is beneficial, particularly in the core age group of 55 to 69 years.
New research on the downstream outcomes following PSA screening may help inform individualized decisions among older men considering screening.
Intermittent androgen deprivation therapy (ADT) may compromise survival for metastatic hormone-sensitive prostate cancer patients compared with continuous ADT, according to a recently published multicenter study.
More than half of prostate cancers detected by PSA measurement are intermediate or high risk at diagnosis, according to findings from a large, population-based study.